Bodysphere EUA Blunder is a Lesson in What Not To Do

Bethany Hills spoke to Medtech Insight for its coverage of Bodysphere’s retracted announcement of its emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a COVID-19 serologic test, which Bethany says should serve as a cautionary tale to other medtech companies.

“Do not release any press releases until you have the EUA letter in hand,” Bethany said. “The second you have it you can release every press release you want, and the FDA will put up the announcement on their website in a few hours.”

Read the full article (subscription required).